twopor
channel
tpc
ca
permeabl
ion
channel
localis
endolysosom
system
regul
traffick
variou
cargo
includ
virus
result
tpc
emerg
import
drug
target
howev
pharmacolog
illdefin
approv
drug
target
mechan
ligand
activ
larg
unknown
identifi
number
fdaapprov
drug
tpc
pore
blocker
use
model
pore
human
base
recent
structur
mammalian
tpc
virtual
screen
databas
approv
drug
tpc
recent
emerg
novel
host
factor
ebola
viru
entri
reason
ebola
viru
entri
inhibitor
may
exert
effect
inhibit
tpc
crossreferenc
hit
tpc
virtual
screen
two
recent
high
throughput
antiebola
screen
yield
approv
drug
target
dopamin
estrogen
receptor
common
hit
compound
inhibit
endogen
naadpevok
ca
releas
sea
urchin
egg
homogen
naadpmedi
channel
activ
rerout
plasma
membran
pi
p
mediat
channel
activ
express
enlarg
lysosom
mechanist
singl
channel
analys
show
drug
reduc
mean
open
time
consist
direct
action
pore
function
drug
potenc
block
activ
correl
inhibit
ebola
viruslik
particl
entri
result
expand
tpc
pharmacolog
identif
approv
drug
novel
blocker
support
role
tpc
ebola
viru
entri
provid
insight
mechan
underli
channel
regul
naadp
potent
ca
mobil
messeng
trigger
ca
releas
acid
ca
store
lysosom
critic
naadp
action
endolysosom
twopor
channel
tpc
local
ca
flux
tpc
increasingli
implic
membran
traffick
event
includ
role
tpc
regul
lysosom
morpholog
retrograd
transport
late
endosom
golgi
endocyt
traffick
receptor
ldl
growth
factor
pigment
granul
integrin
also
like
regul
nonvesicular
traffick
strengthen
membran
contact
site
late
endosom
er
consequ
tpc
fast
emerg
potenti
therapeut
target
divers
disord
parkinson
diseas
fatti
liver
diseas
cancer
moreov
tpc
identifi
novel
host
factor
ebola
viru
ebov
entri
viru
enter
cell
macropinocytosi
traffic
endolysosom
system
follow
bind
intracellular
receptor
fuse
late
endosomeslysosom
releas
genom
cytoplasm
molecular
chemic
inhibit
tpc
prevent
ebov
infect
like
late
entri
step
although
mechan
unclear
tpc
dimer
ion
channel
compris
duplic
domain
architectur
like
bridg
evolut
fourdomain
voltageg
ca
na
channel
atom
structur
plant
mammalian
channel
emerg
provid
detail
insight
architectur
pore
two
isoform
found
human
localis
distinct
compart
within
endolysosom
system
predominantli
localis
late
endosom
lysosom
ntermin
target
motif
mutat
result
rerout
channel
plasma
membran
activ
mechan
ion
select
tpc
area
activ
investig
although
mani
studi
shown
tpc
requir
naadpmedi
ca
signal
naadp
appear
interact
tpc
indirectli
put
bind
protein
contrast
endolysosom
lipid
pi
p
emerg
direct
channel
activ
bind
within
first
domain
tpc
interestingli
residu
linker
within
domain
requir
naadpmedi
ca
signal
fall
within
pi
p
bind
site
indic
complex
interplay
small
molecul
activ
accessori
protein
despit
grow
pathophysiolog
import
tpc
current
select
chemic
tool
inhibit
naadptpc
signal
nalkyl
nicotin
acid
deriv
identifi
ligandbas
virtual
screen
cellperm
inhibitor
naadpevok
ca
signal
indirect
action
coupl
potenti
promiscu
action
target
naadpbind
protein
channel
complic
use
naadp
antagonist
physiolog
set
underscor
need
direct
channel
inhibitor
recent
use
combin
homolog
model
molecular
dock
analys
ca
measur
show
tpc
like
direct
target
number
voltageg
ca
na
channel
modifi
tetrandrin
anoth
ca
channel
antagonist
also
recent
emerg
tpc
blocker
potent
inhibitor
ebov
entri
final
flavonoid
naringenin
shown
block
tpc
low
affin
tetrandrin
naringenin
multipl
target
approv
human
use
worldwid
therefor
limit
number
drug
directli
inhibit
tpc
appli
combin
structur
model
virtual
screen
ca
measur
electrophysiolog
viru
entri
assay
identifi
approv
drug
inhibit
ebov
entri
block
tpc
activ
structur
human
uniprot
access
open
conform
model
cryoem
structur
pi
p
mous
pdb
use
swissmodel
first
residu
exclud
due
lack
appropri
templat
final
model
chosen
use
default
local
model
qualiti
estim
method
qmeandisco
base
novel
version
qmean
addit
model
refin
perform
use
galaxyrefin
conform
librari
drug
set
prepar
use
omega
openey
scientif
softwar
santa
fe
nm
makereceptor
oedock
openey
scientif
softwar
santa
fe
nm
use
gener
activ
site
virtual
screen
centr
pore
vestibul
extend
select
filter
bundl
cross
start
pose
base
blind
dock
verapamil
use
autodock
vina
exhaust
valu
screen
carri
fred
oedock
openey
scientif
softwar
santa
fe
nm
use
default
paramet
return
top
conform
rank
score
tabl
top
rank
conform
ligand
exclud
analysi
retriev
uniqu
drug
metabolit
top
list
tabl
enrich
analysi
top
hit
perform
divid
proport
given
drug
class
within
top
hit
proport
class
screen
whole
drug
classifi
accord
annot
primari
target
analysi
limit
class
drug
class
consid
enrich
valu
ca
releas
assay
use
sea
urchin
egg
homogen
perform
describ
previous
briefli
egg
homogen
load
ca
sequenti
dilut
cytosollik
medium
supplement
atpregener
system
medium
ca
concentr
monitor
fluorimetr
patch
clamp
record
excis
insideout
configur
perform
describ
use
hek
cell
express
human
tag
gfp
cterminu
leucin
replac
alanin
promot
cell
surfac
target
pipett
lumin
solut
contain
mm
nacl
kcl
cacl
mgcl
hepe
me
ph
adjust
naoh
bath
cytoplasm
solut
composit
except
me
exclud
ph
adjust
naoh
osmolar
solut
adjust
mosm
glucos
method
use
record
analys
current
report
previous
pipett
coat
fire
polish
minim
fill
pipett
solut
current
amplifi
use
axopatch
amplifi
filter
khz
db
intern
bessel
filter
digit
khz
digidata
interfac
pclamp
suit
unless
otherwis
state
record
hold
potenti
mv
determin
unitari
current
amplitud
unitari
conduct
current
analys
use
threshold
cross
criterion
use
clampfit
open
briefer
twice
filter
rise
time
exclud
analysi
due
uncertainti
number
channel
record
channel
activ
express
np
kinet
analys
singl
channel
record
simpl
two
state
scheme
c
initi
use
ideal
current
full
bandwidth
khz
use
segment
kmean
skm
hiddenmarkov
algorithm
implement
qub
addit
state
systemat
ad
initi
scheme
variou
topolog
use
mil
modul
qub
dead
time
retrospect
impos
correct
miss
event
mil
fit
gate
scheme
singl
channel
record
optimis
rate
constant
base
maximum
likelihoodbas
markovian
approach
final
gate
scheme
deriv
chang
either
number
state
connect
produc
signific
increment
log
likelihood
ratio
close
time
distribut
analys
channel
activ
reason
high
np
open
singl
current
level
evid
durat
min
analys
perform
follow
naadpdrug
applic
bath
solut
ensur
adequ
mix
lysosom
current
record
use
modifi
patch
clamp
procedur
describ
cell
express
human
tag
gfp
cterminu
briefli
cell
treat
h
result
enlarg
lysosom
access
break
plasma
membran
glass
pipett
pipett
lumin
solut
bath
cytoplasm
solut
contain
mm
nacl
kcl
hepe
ph
naoh
format
seal
lysosom
break
achiev
quick
voltag
step
mv
current
measur
axopatch
patch
clamp
amplifi
control
softwar
current
protocol
use
rapid
alter
membran
potenti
ramp
mv
hold
potenti
mv
interv
current
filter
khz
intern
fourpol
bessel
filter
sampl
khz
store
hard
drive
digidata
viruslik
particl
vlp
ebov
gener
describ
briefli
cell
cotransfect
construct
encod
ebov
matrix
protein
tag
report
nterminu
ebov
glycoprotein
gp
strain
zair
kind
gift
adolfo
garciasastr
cell
maintain
dmem
supplement
vv
fb
streptomycin
unitsml
penicillin
humidifi
atmospher
contain
co
cultur
media
harvest
h
clear
centrifug
vlpcontain
supernat
store
use
vlp
entri
assay
adapt
optimis
plate
format
hela
kyoto
cell
seed
densiti
cellswel
maintain
h
prior
drug
treatment
dmem
supplement
vv
fb
streptomycin
unitsml
penicillin
humidifi
atmospher
contain
co
cell
incub
drug
dmem
vv
fb
h
cultur
condit
prior
addit
vlp
dilut
cell
spinocul
h
follow
incub
h
cultur
condit
allow
vlp
entri
continu
presenc
drug
cell
wash
co
independ
medium
supplement
vv
fb
vv
lglutamin
load
substrat
liveblaz
fretbg
load
kit
invitrogen
accord
manufactur
instruct
use
altern
substrat
load
protocol
cell
trypsinis
fix
paraformaldehyd
min
analys
flow
cytometri
use
lsrii
flow
cytomet
becton
dickinson
usa
collect
least
event
activ
assess
live
cell
flowjo
softwar
packag
determin
proport
blue
fluoresc
cell
cleav
substrat
excit
nm
rel
green
fluoresc
cell
total
substrat
excit
nm
use
filter
set
pacificblu
fitc
respect
data
present
mean
valu
standard
error
mean
indic
concentr
caus
inhibit
ic
hill
coeffici
n
h
deriv
fit
inhibit
curv
use
kaleidagraph
synergi
softwar
recent
advanc
structur
biolog
tpc
provid
novel
opportun
gain
insight
tpc
pharmacolog
thu
appli
structurebas
virtual
screen
approach
identifi
novel
lead
compound
target
tpc
pore
took
advantag
recent
cryoem
structur
mammalian
tpc
model
pore
human
fig
use
model
perform
silico
screen
databas
consist
drug
approv
fda
use
human
result
screen
depict
schemat
fig
compound
rank
accord
score
score
measur
predict
strength
interact
wherebi
neg
valu
indic
stronger
predict
interact
previou
target
dock
analys
show
voltageg
ca
na
channel
blocker
like
interact
tpc
pore
common
ancestr
bind
site
ca
channel
blocker
analys
previous
nicardipin
predict
interact
strongli
pore
diltiazem
potent
function
accordingli
nicardipin
diltiazem
recov
top
rank
blocker
present
screen
fig
asterisk
addit
mean
rank
mean
score
ca
channel
blocker
screen
lower
na
channel
blocker
fig
accord
dock
function
analys
show
avid
interact
potent
inhibit
tpc
blocker
ca
rel
na
channel
taken
togeth
analys
support
unbias
approach
identif
tpc
inhibitor
subsequ
effort
focus
top
hit
recov
virtual
screen
perform
enrich
analysi
accord
primari
target
annot
shown
fig
analysi
reveal
number
drug
target
differ
gprotein
coupl
receptor
hmgcoa
reductas
estrogen
receptor
angiotensin
ii
convert
enzym
unbias
approach
thu
return
number
drug
within
distinct
drug
class
potenti
target
pore
tpc
emerg
novel
host
factor
ebov
infect
reason
fdaapprov
drug
recent
highlight
highthroughput
screen
ebov
entri
inhibitor
might
function
tpc
blocker
thu
compar
top
hit
two
recent
antiebov
screen
togeth
identifi
uniqu
ebov
entri
inhibitor
fig
present
recov
tpc
virtual
screen
fig
notabl
approxim
third
rank
within
top
tpc
screen
fig
inspect
prioritis
hit
compound
fig
reveal
ca
channel
blocker
bepridil
underscor
class
compound
tpc
blocker
importantli
analysi
also
return
dopamin
receptor
antagonist
select
estrogen
receptor
modul
serm
preval
drug
two
class
consist
enrich
analysi
tpc
screen
fig
thu
virtual
screen
pore
physic
screen
ebov
entri
inhibitor
converg
dopamin
receptor
antagonist
serm
candid
tpc
inhibitor
examin
function
drug
tpc
inhibitor
first
test
effect
ca
signal
evok
naadp
use
sea
urchin
egg
homogen
analysi
prepar
consid
gold
standard
assess
naadpmedi
ca
signal
shown
fig
naadp
mediat
robust
ca
signal
larg
block
bepridil
similar
result
obtain
fluphenazin
pimozid
dopamin
receptor
antagonist
fig
also
test
effect
serm
raloxifen
clomiphen
naadp
respons
raloxifen
almost
complet
block
naadpevok
ca
releas
wherea
clomiphen
effect
partial
block
fig
inhibitori
effect
drug
concentr
depend
fig
follow
ic
determin
select
examin
effect
drug
ca
releas
cyclic
adpribos
mediat
effect
ryanodin
receptor
summar
fig
drug
less
effect
inhibit
respons
cyclic
adpribos
naadp
attest
specif
taken
togeth
data
identifi
dopamin
receptor
antagonist
serm
novel
inhibitor
naadp
action
consist
predict
interact
tpc
provid
direct
evid
compound
tpc
blocker
extend
analys
mammalian
system
analys
naadpmedi
channel
activ
human
use
cell
surfac
target
facilit
singl
channel
record
null
background
na
use
major
cation
complement
previou
analys
use
ca
permeant
ion
shown
fig
spontan
activ
note
excis
patch
naadp
addit
bath
solut
robustli
enhanc
channel
activ
concentr
depend
manner
current
amplitud
histogram
shown
fig
c
summari
data
quantifi
normalis
open
probabl
np
shown
fig
analysi
currentvoltag
relationship
indic
unitari
na
conduct
na
ps
fig
n
singl
channel
open
absenc
presenc
naadp
best
fit
singl
exponenti
mean
open
time
ms
fig
subset
record
confid
open
repres
singl
activ
channel
p
min
record
durat
close
time
distribut
also
analys
fig
distribut
best
fit
doubl
exponenti
time
constant
ms
ms
constitut
distribut
respect
n
kinet
model
yield
two
topolog
similar
ratio
linearli
connect
close
state
c
c
open
state
fig
collect
data
affirm
sensit
naadp
permeabl
na
provid
framework
assess
drug
action
singl
channel
level
use
experiment
set
assess
effect
fluphenazin
raloxifen
repres
two
identifi
drug
class
channel
activ
fig
show
continu
uninterrupt
record
channel
activ
respons
naadp
subsequ
addit
drug
drug
acut
inhibit
naadpmedi
channel
activ
fig
also
test
effect
fig
taken
togeth
data
suggest
fluphenazin
raloxifen
effect
behav
pore
blocker
plasma
membran
may
faith
reflect
properti
channel
nativ
environ
perform
electrophysiolog
analysi
enlarg
lysosom
express
wildtyp
fig
experi
stimul
satur
concentr
pi
p
give
larger
current
naadp
experiment
set
like
due
direct
interact
channel
shown
fig
pi
p
stimul
robust
current
lysosom
respons
inhibit
fluphenazin
concentrationdepend
manner
near
full
block
achiev
fig
raloxifen
also
inhibit
pi
p
mediat
current
maxim
effect
fig
inhibitori
effect
drug
revers
upon
washout
fig
concentrationeffect
relationship
show
raloxifen
particularli
potent
block
current
ic
n
h
set
compar
fluphenazin
ic
n
h
respect
fig
final
examin
potenc
dopamin
receptor
antagonist
serm
ebov
entri
surrog
ebov
use
ebola
vlp
carri
follow
fusion
mediat
ebov
glycoprotein
deliv
target
cell
cytoplasm
mediat
cleavag
fluoresc
substrat
fig
quantifi
infect
hela
cell
vlp
infect
block
pretreat
eipa
inhibitor
macropinocytosi
tetrandrin
fig
shown
fig
fluphenazin
pimozid
inhibit
ebola
vlp
entri
ic
valu
n
h
n
h
respect
raloxifen
clomiphen
third
serm
tamoxifen
also
inhibit
entri
ic
valu
n
h
n
h
n
h
respect
enhanc
potenc
serm
rel
dopamin
receptor
antagonist
block
vlp
entri
match
inhibit
current
fig
tpc
channel
physiolog
increasingli
patho
venn
diagram
depict
relationship
approv
drug
identifi
ebola
viru
entri
inhibitor
independ
high
put
screen
kouznetsova
johansen
et
al
b
venn
diagram
depict
relationship
entri
inhibitor
identifi
databas
use
tpc
virtual
screen
c
venn
diagram
depict
relationship
entri
inhibitor
present
databas
top
hit
tpc
virtual
screen
prioritis
set
drug
identifi
c
list
rank
tpc
virtual
screen
report
ic
valu
inhibit
viru
entri
kouznetsova
andor
johansen
et
al
primari
target
annot
physiolog
import
howev
pharmacolog
poorli
defin
current
approv
drug
target
begin
fill
gap
perform
virtual
structurebas
screen
use
databas
approv
drug
pore
region
fig
key
strategi
avail
structur
inform
mammalian
tpc
ii
find
tpc
novel
host
factor
ebov
entri
iii
repurpos
screen
initi
wake
ebola
epidem
yield
number
approv
drug
novel
ebov
entri
inhibitor
prioritis
hit
crossreferenc
latter
wet
data
dri
model
highlight
drug
target
dopamin
estrogen
receptor
fig
drug
demonstr
inhibit
tpc
three
independ
assay
fig
correl
potenc
inhibit
ebola
vlp
entri
fig
singl
channel
analys
confirm
action
drug
pore
fig
result
enrich
analysi
virtual
screen
identifi
number
drug
target
distinct
gprotein
coupl
receptor
fig
notabl
high
throughput
screen
drug
block
ebov
marburg
viru
filovirus
infect
also
highlight
numer
drug
target
gprotein
coupl
receptor
common
drug
class
screen
includ
muscarin
histamin
receptor
link
tpc
ebov
infect
focus
function
analys
dopamin
receptor
antagonist
serm
base
crossreferenc
strategi
fig
compound
repres
fraction
top
hit
thu
screen
offer
consider
scope
identifi
addit
tpc
blocker
futur
dopamin
receptor
drug
identifi
tpc
blocker
includ
sever
phenothiazin
fluphenazin
trifluoperazin
prochlorperazin
thioridazin
use
antipsychot
fig
data
consist
recent
screen
campaign
publish
work
progress
also
identifi
phenothiazin
inhibitor
naadpinduc
ca
releas
sea
urchin
egg
homogen
inde
ic
valu
fluphenazin
fig
compar
congruenc
highlight
power
silico
strategi
drug
identif
togeth
electrophysiolog
analys
point
mechanist
drug
action
tpc
pore
also
identifi
structur
distinct
dopamin
receptor
drug
pimozid
diphenylbutylpiperidin
well
target
dopamin
receptor
pimozid
also
target
voltageg
ca
channel
common
action
pimozid
tpc
voltageg
ca
channel
like
reflect
evolutionari
kindr
two
member
voltageg
ion
channel
superfamili
although
voltageg
ca
channel
implic
viral
entri
function
absenc
nonexcit
cell
hela
cell
use
studi
point
tpc
like
target
analys
identifi
drug
target
estrogen
receptor
addit
tpc
blocker
converg
first
clomiphen
tamoxifen
toremifen
second
raloxifen
third
bazedoxifen
gener
serm
fig
drug
act
estrogen
receptor
agonist
antagonist
depend
tissu
use
treat
breast
cancer
osteoporosi
offtarget
effect
drug
like
relat
wellknown
rapid
nongenom
action
estrogen
inde
inhibit
viral
entri
tpc
activ
submicromolar
concentr
raloxifen
strike
addit
effect
serm
destabilis
either
ebov
glycoprotein
lysosom
membran
due
cation
amphiphil
natur
possibl
nevertheless
dopamin
receptor
antagonist
serm
emerg
novel
tpc
blocker
provid
independ
scaffold
small
molecul
develop
estrogen
receptor
drug
appear
potent
block
tpc
activ
fig
ebola
vlp
entri
fig
dopamin
receptor
drug
correl
point
common
mechan
action
fig
half
maxim
inhibitori
concentr
raloxifen
similar
fluphenazin
effect
inhibit
vlp
entri
fig
block
channel
fig
could
reflect
addit
effect
fluphenazin
underli
entri
inhibit
differ
condit
two
assay
perform
acut
drug
treatment
versu
preincub
broken
versu
intact
cell
one
notabl
differ
rel
poor
potenc
drug
block
ca
signal
egg
homogen
fig
compar
lysosom
current
fig
could
relat
way
drug
administ
activ
ligand
altern
could
point
speci
differ
drug
block
nevertheless
studi
suggest
tpc
may
target
number
ebov
entri
inhibitor
describ
previous
mechanist
inform
lack
tpc
promot
ebov
entri
unclear
present
recent
studi
provid
evid
tpc
may
also
regul
entri
mer
corona
viru
pharmacolog
inhibit
tetrandrin
analogu
molecular
knockdown
tpc
shown
reduc
furin
activ
proteas
activ
requir
prime
envelop
protein
thu
compromis
activ
upon
tpc
blockad
could
underli
reduc
mer
corona
viru
entri
mechan
unlik
regul
entri
ebov
process
endolysosom
cathepsin
moreov
entri
precleav
ebov
also
block
tetrandrin
suggest
tpc
act
step
distal
proteolyt
process
clearli
work
requir
understand
mechan
tpc
involv
ebov
entri
although
cellular
studi
repeatedli
link
tpc
naadpmedi
ca
signal
electrophysiolog
analys
tpc
less
congruent
studi
fail
demonstr
appreci
ca
permeabl
naadp
activ
previou
whole
cell
record
singl
channel
analys
demonstr
robust
activ
ca
cs
current
respons
naadp
use
na
major
permeant
ion
compar
singl
channel
conduct
studi
ps
fig
ca
ps
cs
ps
report
previous
point
strongli
nonselect
cation
channel
experiment
condit
conclus
concur
bilay
studi
electrophysiolog
analys
endogen
naadpactiv
current
record
enlarg
vacuol
na
ca
permeabl
ratio
close
uniti
tpc
interact
mani
protein
like
act
effect
modifi
gate
loss
accessori
factor
might
well
explain
naadp
insensit
studi
inde
loss
might
also
affect
ion
select
tpc
accessori
protein
known
dictat
ion
select
channel
orai
mcu
singl
channel
analys
provid
evid
drug
target
pore
region
tpc
fig
reduct
open
time
modest
rel
reduct
open
probabl
point
open
channel
block
mechan
compat
effect
produc
inhibitor
known
interact
directli
pore
channel
note
phenothiazin
long
exemplar
current
record
enlarg
lysosom
isol
hek
cell
express
lysosometarget
respons
pi
p
hold
potenti
mv
upper
trace
mv
lower
trace
lysosom
challeng
fluphenazin
flu
raloxifen
ral
concentr
time
indic
b
concentrationeffect
relationship
blockad
pi
p
current
fluphenazin
open
circl
raloxifen
close
circl
n
data
normalis
pi
p
respons
absenc
drug
known
antagon
calmodulin
previou
studi
trifluoperazin
suggest
role
calmodulin
naadpmedi
ca
signal
data
fluphenazin
least
suggest
addit
direct
action
phenothiazin
tpc
like
unrel
calmodulin
fig
clearli
structurefunct
analys
warrant
contrast
fluphenazin
raloxifen
affect
open
time
fig
thu
effect
act
gate
modifi
reduc
overal
frequenc
channel
open
directli
indirectli
influenc
channel
region
distal
pore
thu
analys
uncov
fundament
distinct
mechan
channel
inhibit
drug
lack
effect
also
naadp
fig
open
time
support
notion
act
remot
associ
naadpbind
protein
uncertainti
number
channel
well
limit
number
event
patch
low
activ
prevent
us
perform
close
time
distribut
analysi
upon
channel
inhibit
analysi
warrant
least
due
presenc
multipl
close
time
fig
could
reflect
desensit
state
sum
identifi
approv
drug
tpc
blocker
use
novel
strategi
affirm
role
tpc
ebov
entri
significantli
aid
expand
pharmacolog
ubiquit
class
endolysosom
ion
channel
supplementari
data
articl
found
onlin
http
transpar
document
associ
articl
found
onlin
version
concentrationeffect
relationship
blockad
viruslik
particl
entri
indic
dopamin
antagonist
squar
serm
circl
n
